Evidence map›Paper›PMID 35131877›Full record

ArticleMolecular cancer therapeutics2022

Noninvasive Imaging of CD4+ T Cells in Humanized Mice.

Veronica L Nagle, Charli Ann J Hertz, Kelly E Henry, Maya S Graham, Carl Campos, Nagavarakishore Pillarsetty, Andrea Schietinger, Ingo K Mellinghoff, Jason S Lewis

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  3. Reengineered Anti-CD4 Cys-diabody Variants forMolecular imaging and biology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Contribution of Intravital Neuroimaging to Study Animal Models of Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Veronica L NagleDepartment of Pharmacology, Weill Cornell Medical College, New York, New York.
Charli Ann J HertzHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Kelly E HenryDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8492-9364
Maya S GrahamBrain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4748-974X
Carl CamposHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Nagavarakishore PillarsettyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1750-7436
Andrea SchietingerImmunology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Ingo K MellinghoffDepartment of Pharmacology, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-4347-8149
Jason S LewisDepartment of Pharmacology, Weill Cornell Medical College, New York, New York.ORCID 0000-0001-7065-4534
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2M
CLINICAL SCHOLARS BIOMEDICAL RESEARCH TRAINING PROGRAMT32CA009512 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Ping Chi · 1985 to 2026
$6.3M
Molecular Mechanisms of Drug Resistance in Primary Brain TumorsR35NS105109 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI MELLINGHOFF, INGO K · 2018 to 2025
$4.7M
Predoctoral Training in Pharmacological SciencesT32GM073546 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI GROSS, STEVEN S · 2006 to 2020
$3.1M
Horizontal Bore 9.4T Magnet for MRIS10OD023669 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI KOUTCHER, JASON ARTHUR · 2017 to 2017
$600k
NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA232130NCI NIH HHS T32 CA009512NIGMS NIH HHS T32 GM073546NIH HHS S10 OD023669NINDS NIH HHS R35 NS105109
6 · The paper itself

Abstract

Antibody-based PET (immunoPET) with radiotracers that recognize specific cells of the immune system provides an opportunity to monitor immune cell trafficking at the organismal scale. We previously reported the visualization of human CD8+ T cells, including CD8+ tumor-infiltrating lymphocytes (TIL), in mice using a humanized CD8-targeted minibody. Given the important role of CD4+ T cells in adaptive immune responses of health and disease including infections, tumors, and autoimmunity, we explored immunoPET using an anti-human-CD4 minibody. We assessed the ability of [64Cu]Cu-NOTA-IAB41 to bind to various CD4+ T-cell subsets in vitro. We also determined the effect of the CD4-targeted minibody on CD4+ T-cell abundance, proliferation, and activation state in vitro. We subsequently evaluated the ability of the radiotracer to visualize CD4+ T cells in T-cell rich organs and orthotopic brain tumors in vivo. For the latter, we injected the [64Cu]Cu-NOTA-IAB41 radiotracer into humanized mice that harbored intracranial patient-derived glioblastoma (GBM) xenografts and performed in vivo PET, ex vivo autoradiography, and anti-CD4 IHC on serial brain sections. [64Cu]Cu-NOTA-IAB41 specifically detects human CD4+ T cells without impacting their abundance, proliferation, and activation. In humanized mice, [64Cu]Cu-NOTA-IAB41 can visualize various peripheral tissues in addition to orthotopically implanted GBM tumors. [64Cu]Cu-NOTA-IAB41 is able to visualize human CD4+ T cells in humanized mice and can provide noninvasive quantification of CD4+ T-cell distribution on the organismal scale.

Indexed as

CD4-Positive T-LymphocytesCopper RadioisotopesAnimalsCell Line, TumorHumansMicePositron-Emission TomographyCopper-64Copper Radioisotopes

Identifiers

PMID35131877
PMCPMC8983497
OpenAlexW4210868362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.